Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States

Samaneh Kalirai,1 Jasmina I Ivanova,2 Magaly Perez-Nieves,1 Judith J Stephenson,3 Irene Hadjiyianni,1 Michael Grabner,3 Roy Daniel Pollom,1 Caroline Geremakis,3 Beverly L Reed,1 Lawrence Fisher4 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group Inc., New York, NY, USA; 3HealthCore Inc.,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kalirai S, Ivanova JI, Perez-Nieves M, Stephenson JJ, Hadjiyianni I, Grabner M, Pollom RD, Geremakis C, Reed BL, Fisher L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	type 2 diabetes mellitus basal insulin patient survey medication persistence Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/ee0bcfb9873f45e1941eba8d2c0c710c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee0bcfb9873f45e1941eba8d2c0c710c
record_format	dspace
spelling	oai:doaj.org-article:ee0bcfb9873f45e1941eba8d2c0c710c2021-12-02T08:42:48ZBasal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States1178-7007https://doaj.org/article/ee0bcfb9873f45e1941eba8d2c0c710c2020-04-01T00:00:00Zhttps://www.dovepress.com/basal-insulin-initiation-and-maintenance-in-adults-with-type-2-diabete-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Samaneh Kalirai,1 Jasmina I Ivanova,2 Magaly Perez-Nieves,1 Judith J Stephenson,3 Irene Hadjiyianni,1 Michael Grabner,3 Roy Daniel Pollom,1 Caroline Geremakis,3 Beverly L Reed,1 Lawrence Fisher4 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group Inc., New York, NY, USA; 3HealthCore Inc., Wilmington, DE, USA; 4Department of Family and Community Medicine, UC San Francisco, San Francisco, CA, USACorrespondence: Michael GrabnerHealthCore, Inc., 123 Justison St, Suite 200, Wilmington, DE 19801, USATel +1 302 230-2000Email mgrabner@healthcore.comObjective: A survey of US adults with type 2 diabetes mellitus was conducted to better understand patients’ insulin initiation experiences and treatment persistence behaviors.Research Design and Methods: Participants were recruited from consumer panels and grouped by basal insulin treatment pattern: continuers (no gap of ≥ 7 days within 6 months of initiation); interrupters (gap ≥ 7 days, resumed treatment); discontinuers (stopped for ≥ 7 days, not resumed). A quota of approximately 50 respondents per persistence category was set.Results: A total of 154 respondents (52 continuers, 52 interrupters, 50 discontinuers) completed the survey. Mean age was 51.4 years; 51.9% male. Continuers were more likely to report their views being considered during initiation, and less likely to report a sense of failure. Concerns included insulin dependence (64.3% agree/strongly agree), frequent blood glucose monitoring (55.2%), costs/ability to pay (53.9%), fears of or mistakes during self-injection (52.6%), and weight gain (52.6%). Continuers were motivated by benefits of insulin therapy; experienced or potential side effects were notable factors for interruption/discontinuation. Healthcare provider instruction was indicated as a reason for continuing, stopping, and restarting therapy.Conclusion: Benefits of basal insulin therapy motivated continuers while side effects impacted interruption/discontinuation. Persistence on basal insulin is often influenced by provider actions. Earlier provider intervention upon signs of treatment discontinuation may promote persistence.Keywords: type 2 diabetes mellitus, basal insulin, patient survey, medication persistenceKalirai SIvanova JIPerez-Nieves MStephenson JJHadjiyianni IGrabner MPollom RDGeremakis CReed BLFisher LDove Medical Pressarticletype 2 diabetes mellitusbasal insulinpatient surveymedication persistenceSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 1023-1033 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes mellitus basal insulin patient survey medication persistence Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes mellitus basal insulin patient survey medication persistence Specialties of internal medicine RC581-951 Kalirai S Ivanova JI Perez-Nieves M Stephenson JJ Hadjiyianni I Grabner M Pollom RD Geremakis C Reed BL Fisher L Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
description	Samaneh Kalirai,1 Jasmina I Ivanova,2 Magaly Perez-Nieves,1 Judith J Stephenson,3 Irene Hadjiyianni,1 Michael Grabner,3 Roy Daniel Pollom,1 Caroline Geremakis,3 Beverly L Reed,1 Lawrence Fisher4 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group Inc., New York, NY, USA; 3HealthCore Inc., Wilmington, DE, USA; 4Department of Family and Community Medicine, UC San Francisco, San Francisco, CA, USACorrespondence: Michael GrabnerHealthCore, Inc., 123 Justison St, Suite 200, Wilmington, DE 19801, USATel +1 302 230-2000Email mgrabner@healthcore.comObjective: A survey of US adults with type 2 diabetes mellitus was conducted to better understand patients’ insulin initiation experiences and treatment persistence behaviors.Research Design and Methods: Participants were recruited from consumer panels and grouped by basal insulin treatment pattern: continuers (no gap of ≥ 7 days within 6 months of initiation); interrupters (gap ≥ 7 days, resumed treatment); discontinuers (stopped for ≥ 7 days, not resumed). A quota of approximately 50 respondents per persistence category was set.Results: A total of 154 respondents (52 continuers, 52 interrupters, 50 discontinuers) completed the survey. Mean age was 51.4 years; 51.9% male. Continuers were more likely to report their views being considered during initiation, and less likely to report a sense of failure. Concerns included insulin dependence (64.3% agree/strongly agree), frequent blood glucose monitoring (55.2%), costs/ability to pay (53.9%), fears of or mistakes during self-injection (52.6%), and weight gain (52.6%). Continuers were motivated by benefits of insulin therapy; experienced or potential side effects were notable factors for interruption/discontinuation. Healthcare provider instruction was indicated as a reason for continuing, stopping, and restarting therapy.Conclusion: Benefits of basal insulin therapy motivated continuers while side effects impacted interruption/discontinuation. Persistence on basal insulin is often influenced by provider actions. Earlier provider intervention upon signs of treatment discontinuation may promote persistence.Keywords: type 2 diabetes mellitus, basal insulin, patient survey, medication persistence
format	article
author	Kalirai S Ivanova JI Perez-Nieves M Stephenson JJ Hadjiyianni I Grabner M Pollom RD Geremakis C Reed BL Fisher L
author_facet	Kalirai S Ivanova JI Perez-Nieves M Stephenson JJ Hadjiyianni I Grabner M Pollom RD Geremakis C Reed BL Fisher L
author_sort	Kalirai S
title	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
title_short	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
title_full	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
title_fullStr	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
title_full_unstemmed	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
title_sort	basal insulin initiation and maintenance in adults with type 2 diabetes mellitus in the united states
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/ee0bcfb9873f45e1941eba8d2c0c710c
work_keys_str_mv	AT kalirais basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT ivanovaji basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT pereznievesm basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT stephensonjj basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT hadjiyiannii basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT grabnerm basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT pollomrd basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT geremakisc basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT reedbl basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates AT fisherl basalinsulininitiationandmaintenanceinadultswithtype2diabetesmellitusintheunitedstates
_version_	1718398440282521600

Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States

Ejemplares similares